Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Zoledronic acid impairs stromal reactivity by inhibiting M2-macrophages polarization and prostate cancer-associated fibroblasts.

Oncotarget - 3 Jan 2017

Comito Giuseppina, Pons Segura Coral, Taddei Maria Letizia, Lanciotti Michele, Serni Sergio, Morandi Andrea, Chiarugi Paola, Giannoni Elisa

Abstract excerpt

Zoledronic acid (ZA) is a biphosphonate used for osteoporosis treatment and also proved to be effective to reduce the pain induced by bone metastases when used as adjuvant therapy in solid cancers. However, it has been recently proposed that ZA could have direct anti-tumour effects, although the molecular mechanism is unknown. We herein unravel a novel anti-tumour activity of ZA in prostate cancer (PCa), by...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-Associated Fibroblasts
Share to Diphosphonates

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Imidazoles

Share to Macrophage Activation

Share to Mevalonic Acid

Share to Neovascularization, Pathologic

Share to rhoA GTP-Binding Protein

Share to Stromal Cells

Source

Open in PubMed Open full text

Identifiers

PMID: 27223431
DOI: 10.18632/oncotarget.9497
PMCID: PMC5352046

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Zoledronic acid impairs stromal reactivity by inhibiting M2-macrophages polarization and prostate cancer-associated fibroblasts.PMID 27223431Read ↗

Treatment with Cannabinoids as a Promising Approach for Impairing Fibroblast Activation and Prostate Cancer Progression.Semantic proximity Read ↗

Tumor microenvironment and metabolism in prostate cancer.Semantic proximity Read ↗

Prostate cancer-induced endothelial-to-osteoblast transition generates an immunosuppressive bone tumor microenvironmentSemantic proximity Read ↗

Inhibition of glypican-1 expression induces an activated fibroblast phenotype in a human bone marrow-derived stromal cell-line.Semantic proximity Read ↗

SFRP2 Overexpression Induces an Osteoblast-like Phenotype in Prostate Cancer Cells.Semantic proximity Read ↗

Silibinin prevents prostate cancer cell‐mediated differentiation of naïve fibroblasts into cancer‐associated fibroblast phenotype by targeting TGF β2Semantic proximity Read ↗

Kaurenoic Acid Suppresses Osteosarcoma Progression by Reprogramming Tumor-Associated Macrophages to M1 Phenotype.Semantic proximity Read ↗

PKA-driven SPP1 activation as a novel mechanism connecting the bone microenvironment to prostate cancer progressionSemantic proximity Read ↗

Runx2 transcriptome of prostate cancer cells: insights into invasiveness and bone metastasisSemantic proximity Read ↗

Dual-Lineage Human 3D Bone Niche Model Reveals Osteoclast-Driven Osteomimicry in Prostate CancerSemantic proximity Read ↗

Acquired resistance to zoledronic acid and the parallel acquisition of an aggressive phenotype are mediated by p38-MAP kinase activation in prostate cancer cells.Semantic proximity Read ↗

Bone morphogenetic proteins and their receptor signaling in prostate cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.